Alpha DNA Investment Management LLC Acquires Shares of 3,019 Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)

Alpha DNA Investment Management LLC acquired a new position in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report) during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The fund acquired 3,019 shares of the biopharmaceutical company's stock, valued at approximately $710,000.

Other large investors also recently bought and sold shares of the company. CANADA LIFE ASSURANCE Co boosted its stake in shares of Alnylam Pharmaceuticals by 11.9% in the fourth quarter. CANADA LIFE ASSURANCE Co now owns 76,919 shares of the biopharmaceutical company's stock worth $18,087,000 after acquiring an additional 8,206 shares during the last quarter. Marshall Wace LLP boosted its stake in Alnylam Pharmaceuticals by 496.6% during the 4th quarter. Marshall Wace LLP now owns 378,649 shares of the biopharmaceutical company's stock worth $89,100,000 after purchasing an additional 315,182 shares during the last quarter. NewEdge Advisors LLC grew its holdings in shares of Alnylam Pharmaceuticals by 97,200.0% during the fourth quarter. NewEdge Advisors LLC now owns 973 shares of the biopharmaceutical company's stock worth $229,000 after buying an additional 972 shares in the last quarter. Jump Financial LLC acquired a new stake in shares of Alnylam Pharmaceuticals in the fourth quarter valued at about $3,564,000. Finally, Bridgewater Associates LP lifted its stake in shares of Alnylam Pharmaceuticals by 222.3% in the fourth quarter. Bridgewater Associates LP now owns 6,452 shares of the biopharmaceutical company's stock worth $1,518,000 after buying an additional 4,450 shares in the last quarter. 92.97% of the stock is currently owned by hedge funds and other institutional investors.

Alnylam Pharmaceuticals Stock Up 1.6 %

Shares of NASDAQ ALNY traded up $3.72 during midday trading on Wednesday, hitting $240.47. The company's stock had a trading volume of 290,767 shares, compared to its average volume of 872,052. The company has a debt-to-equity ratio of 15.27, a current ratio of 2.78 and a quick ratio of 2.71. The firm has a market capitalization of $31.28 billion, a price-to-earnings ratio of -110.82 and a beta of 0.30. The business's fifty day simple moving average is $247.91 and its two-hundred day simple moving average is $256.50. Alnylam Pharmaceuticals, Inc. has a 1 year low of $141.98 and a 1 year high of $304.39.

Alnylam Pharmaceuticals (NASDAQ:ALNY - Get Free Report) last issued its quarterly earnings results on Thursday, February 13th. The biopharmaceutical company reported ($0.65) EPS for the quarter, missing the consensus estimate of ($0.62) by ($0.03). On average, equities analysts predict that Alnylam Pharmaceuticals, Inc. will post -1.7 EPS for the current year.

Analyst Ratings Changes

A number of analysts have commented on the stock. JPMorgan Chase & Co. upgraded shares of Alnylam Pharmaceuticals from a "neutral" rating to an "overweight" rating and increased their price objective for the company from $280.00 to $328.00 in a report on Monday, March 24th. StockNews.com upgraded Alnylam Pharmaceuticals from a "hold" rating to a "buy" rating in a research report on Tuesday. Stifel Nicolaus boosted their price objective on Alnylam Pharmaceuticals from $300.00 to $345.00 and gave the stock a "buy" rating in a research note on Monday, March 31st. Royal Bank of Canada raised their target price on Alnylam Pharmaceuticals from $310.00 to $330.00 and gave the stock an "outperform" rating in a research note on Friday, March 21st. Finally, Needham & Company LLC reissued a "buy" rating and set a $320.00 price target on shares of Alnylam Pharmaceuticals in a research report on Wednesday, April 9th. One equities research analyst has rated the stock with a sell rating, four have assigned a hold rating and twenty-two have issued a buy rating to the company. Based on data from MarketBeat.com, the stock has an average rating of "Moderate Buy" and an average target price of $315.58.

Insiders Place Their Bets

In other news, CFO Jeffrey V. Poulton sold 967 shares of Alnylam Pharmaceuticals stock in a transaction on Friday, February 14th. The shares were sold at an average price of $255.17, for a total transaction of $246,749.39. Following the completion of the sale, the chief financial officer now directly owns 32,786 shares of the company's stock, valued at approximately $8,366,003.62. The trade was a 2.86 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO Yvonne Greenstreet sold 1,213 shares of the stock in a transaction on Friday, February 14th. The shares were sold at an average price of $255.17, for a total value of $309,521.21. Following the completion of the transaction, the chief executive officer now directly owns 81,526 shares in the company, valued at $20,802,989.42. This trade represents a 1.47 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 71,234 shares of company stock worth $19,958,097 in the last quarter. 1.20% of the stock is owned by company insiders.

Alnylam Pharmaceuticals Company Profile

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.